 "Sequent Scientific buys Lyka's animal business")
Alivira Animal Health Limited, a subsidiary of Sequent Scientific, on August 28, 2015 signed an agreement to acquire the animal health business of Lyka Exports, a subsidiary of Lyka Labs Litd, on a 'going concern' basis. The proposed acquisition of Lyka’s animal health business includes all IPRs, sales/marketing/distribution network with related employees, contracts, assets and liabilities.
Manish Gupta, managing director, Sequent Scientific, said, “This acquisition augurs well for achieving Alivira's strategic objective of emerging a power house in the global animal healthcare space. The business being acquired will strengthen our portfolio in cattle and dairy segment and will complement our existing India formulations business."
In FY15, Lyka’s animal health business registered a top line of close to Rs 23.50 crore with EBITDA margins in the range of 12%. The business is growing by over 30% during the ongoing financial year (FY16).
Commenting on the development, N I Gandhi, chairman, Lyka, said, “The transaction, while strengthening our financials, also allows us to focus on creating value in the core pharma business. The proceeds will be predominately utilised to pare down debt. With Sequent's focus and intent to develop a strong global animal health business in Alivira, the transaction offers great opportunities to the employees who are moving to the Sequent family.”
Manish Gupta, managing director, Sequent Scientific, said, “This acquisition augurs well for achieving Alivira's strategic objective of emerging a power house in the global animal healthcare space. The business being acquired will strengthen our portfolio in cattle and dairy segment and will complement our existing India formulations business."
In FY15, Lyka’s animal health business registered a top line of close to Rs 23.50 crore with EBITDA margins in the range of 12%. The business is growing by over 30% during the ongoing financial year (FY16).
Commenting on the development, N I Gandhi, chairman, Lyka, said, “The transaction, while strengthening our financials, also allows us to focus on creating value in the core pharma business. The proceeds will be predominately utilised to pare down debt. With Sequent's focus and intent to develop a strong global animal health business in Alivira, the transaction offers great opportunities to the employees who are moving to the Sequent family.”
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%